Use of Erbium Laser for Extraction of the Third Molars
Launched by I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY · Sep 9, 2022
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to remove impacted lower third molars, commonly known as wisdom teeth, using an erbium laser. The study will compare the effectiveness of this laser technique to traditional methods of extraction. Researchers will evaluate various factors like healing and recovery through clinical exams, x-rays, and blood tests after the procedure.
To participate in this trial, you need to be between 25 and 50 years old and have a wisdom tooth that needs to be removed. You must also be in good health and have no major dental issues like infections or gum disease. If you join the study, you will receive either the laser treatment or the traditional method, and you'll be monitored closely to see how well each technique works. It's important to note that the trial is not yet recruiting participants, so it will start soon. If you're interested, be sure to discuss it with your dentist to see if it's a good option for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Signing of written informed consent of the patient to participate in a study
- • 2. Age from 25 to 50 years old
- • 3. Indications for impacted third molar extraction
- • 4. Patients who are medically stable
- • 5. Therapeutic and surgical oral hygiene before surgery (absence of inflammatory diseases, caries, pulpitis, periodontitis in oral cavity)
- Exclusion Criteria:
- • 1. Refusal of the patient from further participation in the study
- • 2. Pregnancy diagnosed after the inclusion into the trial
- • 3. Non-compliance by the patient with postoperative recommendations
- • 4. Absence of a lower second molar
About I.M. Sechenov First Moscow State Medical University
i.m. Sechenov First Moscow State Medical University is a prestigious institution dedicated to advancing medical education, research, and clinical practice. As a leading center for medical innovation in Russia, the university fosters a collaborative environment for scientific inquiry and the development of novel therapies. With a commitment to high-quality clinical trials, i.m. Sechenov aims to contribute significantly to the global biomedical landscape by evaluating new treatments and improving patient care through rigorous research methodologies and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Diana Sologova
Principal Investigator
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials